You are here

Update on Theta Burst TMS and TMS for OCD - New FDA Information

×

Warning message

This Grand Rounds Webinar is restricted to registered participants or on-demand registrants. Click the following link to register: Register Here

Presenting: Update on Theta Burst TMS and TMS for OCD ~ New FDA Information 

Learning objectives: 

  1. To learn about the recently FDA cleared use of theta burst tms for depression;
  2. To review the FDA clearance of TMS for treatment of OCD;
  3. To learn about the OCD treatment protocol, including symptom induction

Format: On-demand
Release Date: October 10, 2018
Expiration Date: October 9, 2020

Cost: Members: $25 | Non-members $50

Method of Physician Participation: Learners will listen to each audio self-directed module while following along with the visual slides. Upon completion, each learner will answer evaluation questions to receive their CME Certificate.

Bibliographic Sources: See slides for bibliographic sources for further study.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco.  All of these relationships were treated as a conflict of interest and have been resolved.  (C7 SCS 6.1-­‐6.2, 6.5)

All individuals in a position to control the content of CE are listed in the program book. If their name is not listed below, they disclosed that they had no relevant financial relationships with commercial interests. 

First Name

Last Name

Commercial Interest: Relationship

Michelle

Cochran

Genomind: Speakers Bureau

Kimberly

Cress

Speaker for Neuronetics & Medical Director of Houston NeuroCare Therapy

Adrianne

Davis

Nothing to disclose

Deborah

Kim

Nothing to disclose

Sheryl

Morgan

Nothing to disclose

Randy

Pardell

Nothing to disclose

 

 


Speakers: Daniel Press, MD & David Feifel, MD, PhD
Dr. Press received his undergraduate degree from the University of Pennsylvania and his medical degree from the University of Connecticut School of Medicine.  He trained in Neurology at the Harvard Longwood Neurology Training Program and did fellowship training in both Behavioral Neurology  (1997-1999) and Movement Disorders (1999-2000).  He is the Clinical Director fo the Cognitive Neurology Unit at BIDMC and is currently an Associate Professor in Neurology at Harvard Medical School.  He is the Clinical Director of the Berenson Allen Center for Noninvasive Brain Stimulation at Beth Israel Deaconess Medical Center and is the co-chair of the Clinical Standards Committee of the Clinical TMS Society, where he is also a board member.  He has over 40 publications in TMS and related fields, and does NIH funded clinical studies in TMS.

Dr. Feifel earned a Bachelor of Science, Master’s Degree and a Ph.D. (neurobiology) from the University of Toronto, Canada, where he also earned a Medical Degree. After completing an internship in Internal Medicine at the Toronto General Hospital, Dr. Feifel completed his residency training in Psychiatry at the University of California, San Diego, where he served as Chief Resident for the UCSD Outpatient Psychiatry Services in 1994.  He currently holds the rank of full Professor in the Department of Psychiatry and Neuroscience Program.   Dr. Feifel conducts translational research in mental illness and he has authored or co-authored numerous original scientific research papers, abstracts and book chapters on the topic of psychiatric illness and their treatments.  His research has received funding grants from the National Association for Research in Schizophrenia and Depression (NARSAD), the Scottish Rite Organization, the Stanley Medical Research Institute and the National Institutes of Health. Dr. Feifel is Director of the Neuropsychiatry and Behavioral Medicine Program, and he is the founder and Director of the UCSD Adult ADHD Program, as well as the UCSD TMS program. 


 

Vertical Tabs

Vertical Tabs

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the Clinical TMS Society. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Credit Designation Statement – Amedco LLC designates this enduring material activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Credit Designation Statement – Amedco LLC designates this enduring material activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.